Mpex Pharmaceuticals Initiates Multi-Dose Clinical Trial In The U.S. With MP-376 In Patients With Cystic Fibrosis
Mpex Pharmaceuticals, Inc. today announced the initiation of a Phase 1b clinical trial with its lead compound, MP-376, in patients with cystic fibrosis (CF). MP-376 is a proprietary aerosolized formulation of the antibiotic levofloxacin that is being developed for the treatment of chronic lung infections due to Pseudomonas aeruginosa in CF patients.
